EKF Diagnostics Holdings PLC Completion of ADL Health Acquisition (7207O)
12 Octubre 2021 - 1:00AM
UK Regulatory
TIDMEKF
RNS Number : 7207O
EKF Diagnostics Holdings PLC
12 October 2021
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Completion of acquisition, Admission & TVR Update
Capitalised terms in this announcement carry the same meaning as
in the
RNS of 28 September 2021, unless otherwise stated
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business , announces that, further to the
announcement on 28 September, the Acquisition of ADL Health has
completed.
Admission of the Consideration Shares to trading on AIM and
Total Voting Rights
Application has been made for admission of 8,937,337
Consideration Shares to trading on the AIM Market of the London
Stock Exchange ("Admission") based on an exchange rate of
US$1.37115:GBP1. Admission is expected to take place on 14 October
2021.
The Consideration Shares will, when issued, be credited as fully
paid new ordinary shares and will rank equally in all respects with
the existing ordinary shares, including the right to receive any
dividend or other distribution declared, made or paid after
Admission.
For the purposes of the Financial Conduct Authority's Disclosure
Guidance and Transparency Rules ("DTRs"), the issued ordinary share
capital of the Company following Admission will consist of
463,930,564 ordinary shares each carrying one voting right. There
are no ordinary shares held in treasury. From the date of
Admission, the figure of 463,930,564 may be used by shareholders as
the denominator for the calculations by which they will determine
whether they are required to notify their interests in, or a change
to their interest in, the Company under the DTRs.
For further information please contact:
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Mike Salter, CEO Via Walbrook PR
Singer Capital Markets (Nominated Adviser Tel: +44 ( 0)20 7496 3000
& Joint Broker)
Aubrey Powell / George Tzimas / Tom Salvesen
Investec Bank plc (Joint Broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analysers in regular use
across more than 100 countries. EKF specialises in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analysers.
EKF specialises in the development, production and worldwide
distribution of point-of-care analyzers and clinical chemistry
reagents for use in hospital and research laboratories, doctor's
offices, blood banks and for in-field anaemia screening programmes.
EKF is also a bulk manufacturer of enzymes and has custom
manufacturing facilities in the across sites in the US, UK and
Europe for a variety of life science products. Demand for contract
manufacturing of COVID-19 sample collection tests and kits has
grown dramatically during the pandemic, however the capabilities
can be applied to other areas of diagnostic testing, molecular
disease and forensic test manufacture.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBRBDGISBDGBB
(END) Dow Jones Newswires
October 12, 2021 02:00 ET (06:00 GMT)
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ekf Diagnostics (LSE:EKF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024